ATORG-5
Undisclosed solid tumors
PreclinicalIn development
Key Facts
Indication
Undisclosed solid tumors
Phase
Preclinical
Status
In development
Company
About Alligator Bioscience AB
Alligator Bioscience is dedicated to developing innovative antibody-based cancer immunotherapies. The company's core strategy revolves around its proprietary technology platforms designed to generate highly specific and potent antibodies. Its most advanced asset, mitazalimab (a CD40 agonist), is being evaluated in a pivotal Phase 2 trial for metastatic pancreatic cancer, a significant unmet medical need. The company also has a strategic partnership with Orion Corporation for the development of bispecific antibodies and collaborates with other biopharmaceutical firms.
View full company profileTherapeutic Areas
Other Undisclosed solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GLX-401 | Genelux | Preclinical |
| Immuno-Oncology Platform Candidate(s) | OSE Immunotherapeutics | Preclinical to Phase 1/2 |